


Oslo  (Norway), 5 September 2017 - Exercise of employee share options, mandatory
notification  of  trade  and  resolution  to  increase  the share capital in PCI
Biotech Holding ASA (the "Company").

1.   Options exercised and mandatory notification of trade
Participants in the Company's share option program have on September 5(th) 2017
exercised  a  total  number  of  86,500 share  options  at a strike price of NOK
19.90, corresponding  to a total  number of 86,500 shares.  All of the exercised
share options expired on September 5(th) 2017.

Out  of the  total number  of exercised  share options, 38,000 share options are
exercised by the following primary insiders, who, in turn, have sold such number
of  shares in the  market as is  necessary in order  to finance the cash and tax
impact of the exercise:

Per  Walday, CEO, exercised 16,000 share options  at a subscription price of NOK
19.90 per  share and  has sold  14,428 shares at  NOK 24.62 per share. After the
transaction, Mr. Walday will hold 65,133 shares and 104,000 share options in the
Company.

Anders  Høgset, CSO, exercised  11,000 share options at  a subscription price of
NOK  19.90 per share and has sold 9,919 shares at NOK 24.62 per share. After the
transaction,  Mr. Høgset will hold 62,456 shares and 66,000 share options in the
Company.

Kristin Eivindvik, PD, exercised 11,000 share options at a subscription price of
NOK  19.90 per share and has sold 9,919 shares at NOK 24.62 per share. After the
transaction,  Ms. Eivindvik will hold  17,948 shares and 33,500 share options in
the Company.

This  announcement also represents  a mandatory notification  of trade, which is
submitted by the Company on behalf of such primary insiders.

2.   Resolution to increase the share capital
Following  the exercise of share  options on September 5(th) 2017, the Company's
Board of Directors, pursuant to an authorisation granted by the Company's Annual
General  Meeting on May  29th 2017, has decided to  increase the Company's share
capital  with NOK 259,500 by issuing 86,500 new  shares, each share of par value
NOK 3.00. Subsequent to the transaction, the Company's share capital will be NOK
74,960,670 divided  into 24,986,890 shares. The capital  increase will result in
gross proceeds of NOK 1,721,350.

Contact information:
Ronny Skuggedal, CFO
rs@pcibiotech.no
Mobile: +47 9400 5757

This  information is subject to the  disclosure requirements pursuant to section
5 -12 of the Norwegian Securities Trading Act.


 
    